The 2016 revised fourth edition of the World Health Organization (WHO) classification of
central nervous system (CNS) tumors incorporated molecular features with histologic …

Abstract Background The World Health Organization (WHO) Classification of Tumours, also
known as WHO Blue Books, represents an international standardised tool in the diagnostic …

Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …

Meningiomas currently are among the most frequent intracranial tumours. Although the
majority of meningiomas can be cured by surgical resection,∼ 20% of patients have an …

Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop
meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary …

Meningiomas are classified based on histological features, but genetic and epigenetic
features are emerging as relevant biomarkers for outcome prediction and may supplement …

Background There is a critical need for objective and reliable biomarkers of outcome in
meningiomas beyond WHO classification. Loss of H3K27me3 has been reported as a …

Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled
receptor and can be activated by somatostatin or its synthetic analogs. SSTR2 is therefore …

Mitosis is a critical criterion for meningioma grading. However, pathologists' assessment of
mitoses is subject to significant inter-observer variation due to challenges in locating mitosis …

Meningiomas are the most common intracranial tumors in adult patients. Although the
majority of meningiomas are diagnosed as benign, approximately 20% of cases are high …